Research into the Causes of Venom-Induced Mortality and Morbidity Identifies New Therapeutic Opportunities. by Girish, Kesturu S et al.
Am. J. Trop. Med. Hyg., 100(5), 2019, pp. 1043–1048
doi:10.4269/ajtmh.17-0877
Copyright © 2019 by The American Society of Tropical Medicine and Hygiene
Perspective Piece
Research into the Causes of Venom-Induced Mortality and Morbidity
Identiﬁes New Therapeutic Opportunities
Kesturu S. Girish,1,2 Gajanan D. Katkar,1,3 Robert A. Harrison,4 and Kempaiah Kemparaju1*
1Department of Studies in Biochemistry, University of Mysore, Mysuru, India; 2Department of Studies and Research in Biochemistry, Tumkur
University, Tumakuru, India; 3Cardiovascular Research Lab, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan; 4Centre for
Snakebite Research and Interventions, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
Abstract. Snakebite primarily affects rural subsistent farming populations in underdeveloped and developing
nations. The annual number of deaths (100,000) and physical disabilities (400,000) of snakebite victims is a societal
tragedy that poses a signiﬁcant added socioeconomic burden to the society. Antivenom therapy is the treatment of
choice for snakebite but, as testiﬁed by the continuing high rates of mortality and morbidity, too many rural tropical
snakebite victims fail to access effective treatment. Here, we advocate for more basic research to better understand
the pathogenesis of systemic and local envenoming and describe how research outcomes can identify novel
snakebite therapeutic strategies with the potential to be more accessible and affordable to victims than current
treatment.
INTRODUCTION
Snakebite is a daily, domestic, occupational, and environ-
mental hazard in the tropical countries of Asia, Africa, and
Latin America.1–4 Of the 1.8–2.7 million people bitten annually
by snakes, approximately 81,000–138,000 victims die and
about 400,000 survivors suffer from permanent physical dis-
abilities.5 The snakebite mortality and morbidity ﬁgures may
be a substantial underestimate becausemany, perhapsmost,
victims do not access hospital care and their deaths and
disabilities are therefore not recorded. For example, a recent
community-based study1 undertaken throughout India (as
part of the million deaths project) identiﬁed that snake enve-
noming kills 46,000 victims a year—signiﬁcantly more than
had been estimated previously. Thus, the continuing high
rates of mortality and morbidity indicate the scale of the
problem. Despite this being a global threat, snakebite remains
more of a poor man’s problem; furthermore, unlike infectious
diseases to which the world pays greater attention, the non-
infectious nature of snakebite could also be the reason for it’s
negligence. The epidemiological data reveals that children
and adults, mostly the breadwinners of the families, from the
weaker socioeconomic background engaged in subsistence
farming are the most vulnerable to snakebite.5 The affected
families thus suffer from sustained socioeconomic crisis in-
cluding child development and income loss. There are studies
reported that the contribution of snakebite to disease burden
is half the disease burden of HIV/AIDS in developing and un-
derdeveloped countries.6 This disease burden is likely to be
replicated in many tropical and subtropical countries and
underscores the need for immediate attention to deliver more
accurate medical care, including sensitizing national and
international health policy-making.
Research into antivenom production for snakebite treat-
ment has a long history, starting with Albert Calmette in
1894 who pioneered anti-snake venom serum for snake-
bite victims.7,8 Since then, intravenous infusion of antivenom
remains an exclusive therapy; however, there have been in-
novations over the past century. These include purifying IgG
fractions from the serum of various animals (horse, camel,
sheep and donkey) immunized with venom.9,10 Furthermore,
researchers in the past have also been motivated to produce
therapeutic F(ab)2 and Fab fragments from anti-snake venom
IgG through limited proteolysis.11–13 This was to reduce the
risk of serum sickness due to overdosage of antiserum and to
augment the neutralizing efﬁcacy by increasing the number of
paratopes per unit mass of antivenom. Presently, there are
more than 45 antivenom-manufacturing companies using
these protocols to produce a number of brands of IgG, F(ab9)2,
or Fab antivenom for global use.14–19
Antivenom therapy: Factors reducing the efﬁcacy.
Snakebite is an example of a simultaneous potential le-
thal assault on vital systems such as nervous, muscular, and
circulatory systems. These systems are functionally interde-
pendent such that the effect on one system can affect the
others, and thus, it is a precarious medical emergency. De-
spite advancement in snake venom research, there are very
limited treatment options, except for the usage of antivenom
therapy to save snakebite victims, including the lack of life
saving ﬁrst-aid protocols. Although antivenom remains the
sole therapy as of now, the global high rates of mortality and
morbidity reported by various studies underscore the serious
drawbacks of the antivenom therapy.20–22 Three factors have
been considered to critically affect the efﬁcacy and success
rate of the antivenom therapy: ﬁrst, the delay between the time
of the bite and the start of antivenom therapy (these have a
reciprocal relationship). In most affected nations, victims are
transported long distances from remote places to health-care
centers. Furthermore, scarcity of antivenom therapy even at
tertiary health-care centers is also a matter of concern, thus
extending the delay. Second is the polyvalent nature of the
therapeutic antivenom: for example, in India, polyvalent anti-
venom (prepared against the venoms of “big four” snakes:
cobra, krait, Russell’s viper, and saw-scaled viper) is the only
antivenom in use for the treatment. Thus, the efﬁcacy of the
therapy against the speciﬁc case of envenomation is likely to
be reduced by 1/4. Third is the venom variability, which is con-
sidered at different levels, such as inter-family, inter-genus,
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inter-species and subspecies, and within species.23–27 Of
these, the variability within the species is considered to be
perilous, especially variability due to the varied geographic
distributionof snakespecies.Nevertheless, it is also important
to realize the fact that several studies endorse the venom
variability within the species because of age, season, gender,
and diet variations in addition to geographic variations.23,25
Thus, venomvariability appears to be an innate character and
could be controlled by multiple factors regulating through
epigenetic and othermodiﬁcations. To tackle this, in a country
like India several studies strongly recommend the use of re-
gion speciﬁc antivenom.28
Although antivenom therapy saves the lives of hundreds
and thousands of snakebite victims, the high rate of mortality
is a strong indicator of underlying deﬁciencies. Furthermore,
the therapy is unsuccessful against the sustained tissue ne-
crosis induced at the bite site by the vipers and some cobras.4
Thus, under critical circumstances, continued tissue necrosis
may only be prevented through amputation of the affected
limb; this results in permanent disability or disﬁgurement.
Thus, achieving successful treatment against the sustained
tissue necrosis is challenging and still remains a grey area.
Therefore, it is important to evaluate options for the existing
antivenom therapy so that an effective therapy that would
reduce the rates of both mortality and morbidity may be
achieved. Here, we describe efforts to identify the mecha-
nisms of these pathologies and how this improved un-
derstanding leads to the novel potential therapies, including
those potentially suitable as “ﬁrst response” measures.
The pathogenesis and reversal of snake venom–induced
local tissue destruction. Envenoming by many vipers
and some cobras can cause profound local tissue destruction
at the bite site. Figure 1 illustrates the impact of the fearful,
debilitating, tissue-destructive effects of envenoming by the
West African saw-scaled viper Echis ocellatus.21 Because
antivenom is ineffective in treating this condition (unless it is
given very soon after the bite, which is rare in rural remote
regionsat greatest risk), surgical debridementor amputation is
required to manage this pathology. This dreadful event
remained unaddressed all these years as there were no suit-
able models to investigate the molecular mechanism. Our
laboratory has established a mouse-tail model and in-
vestigated the inﬂammatory response to Echis carinatus (In-
dian saw-scaled viper) venom.
We have reported29 that E. carinatus venom induces a
strong inﬂammatory response at the injection site starting
with an inﬂux of neutrophils (polymorphonuclear leuko-
cytes). They are the ﬁrst line of defense cells and major
phagocytes of innate immunity. As an ultimate defense,
neutrophils commit suicide, resulting in the release of their
de-condensed DNA ﬁbers/chromatin, which form struc-
tures called neutrophil extracellular traps (NETs) by a pro-
cess called NETosis.30–34We showed that E. carinatus venom
readily elicits intense and stable NETs at the injection site
through a mechanism dependent on reactive oxygen spe-
cies (ROS). The extruded DNA ﬁbers/chromatin (NETs)
from hundreds and thousands of neutrophils form a physical
plug in the blood vessels that 1) prevents blood ﬂow to tail
tissue distal from the venom injection site, 2) sequesters
venom toxins in that site through ionic interactions, and 3)
causes accumulation of toxic metabolites, and hypoxia. Fur-
thermore, sequestration of venom toxins, such as the extra-
cellular matrix (ECM)–degrading hemorrhagic snake venom
metalloproteases (SVMPs), resulting in the degradation of
FIGURE 1. The pictures represent the gravity of snakebite-induced sustained tissue decay at the bite site. Case 1: (A) initial examination showed
that the right hand and forearmwere swollen, (B) initial perioperative observations, and (C) after wound cleaning. Case 2: (A) initial aspect of the left
hand, (B) fasciotomy, and (C) clean aspect of the hand, after eight surgeries. Figures reprinted fromRef. 21.Copyright byCEVAP/UNESP.Reprinted
with permission. This ﬁgure appears in color at www.ajtmh.org.
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blood vessels and surrounding tissues. Together, these sus-
tained effects resulted in tail tissue necrosis.29
We reasoned that dismantling the DNA ﬁbers/NETs
should restore blood ﬂow before the death of cells and
tissues, and thereby prevent the onset of necrosis. Indeed,
injection of deoxyribonuclease 1 (DNase 1) even 3 hours
after the venom injection to the same site prevented ne-
crosis (Figure 2) and enabled full physiological recovery of
tail tissue.29
We have extended our research into the mechanisms of
venom-induced tissue destruction. Neutrophils, monocytes
(peripheral blood mononuclear cells), and platelets are the
key players of the inﬂammatory response and wound-
healing process and express transmembrane surface re-
ceptors for collagen, including integrin α2β1, glycoprotein
VI, and discoidin domain receptor 1. These receptors regu-
late a spectrum of cellular functions including adhesion, mi-
gration, differentiation, hemostasis, and immune functions.35–41
FIGURE 2. Deoxyribonuclease (DNase) 1 treatment prevents Echis carinatus venom-induced tissue destruction in the challenge study. (A) The
graph represents the continued tail injury score in E. carinatus venom (LD50)-injected mouse tails (red line), whereas the administration of 100U
DNase 1 at various times (30–180minutes post-venom injection) decreased the tail injury score. PBS = Posphate buffer saline. (B) Representative
photographs of mice taken on different days after injection. The mice were injected with E. carinatus venom (LD50; top row) or co-injected with
E. carinatus venom (LD50) and DNase 1 (100U; bottom row); the mice in the latter group recovered, and normal tail morphology was restored from
day 4 onward (bottom, third). Scale bars, 2 cm (n = 10). Figures reprinted from Ref. 29 with permission. This ﬁgure appears in color at www.ajtmh.org.
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Peripheral blood mononuclear cells also express the CX3
chemokine receptor 1, which is essential for angiogenesis
and wound-healing processes.40 We demonstrated that 1)
E. carinatus venom SVMPs, in addition to destroying the ECM,
also degrade these receptors, resulting in the inhibition of the
adhesion of inﬂammatory cells and hence inhibition of angio-
genesis andwound-healingevents, and2) thesevenom-induced
effects can be reversed by a lupeol-derivative treatment.41
These studies demonstrate the value of research into the
mechanisms of venom-induced tissue necrosis and indicate
that surface application of SVMP inhibitors is likely to enhance
angiogenesis and wound-healing processes, and injection of
DNase 1 to break down NETs could be an effective treatment
of snake venom-induced tissue necrosis.
The pathogenesis and reversal of venom-induced sys-
temic toxicity with “ﬁrst-response” treatment at the
community level. Lack of adequate health-care facilities in the
underdeveloped and developing countries leads to delayed
treatments after a snakebite. We reasoned that the delay in
snakebite treatment may cause additional pathologies related
to theacutephase responseofneutrophilsandothercirculating
blood cells associated with hypoxia. We also sought to identify
a treatment that could be safely applied in the community to
reduce/delay the severity of systemic snake venom pathology.
Neutrophils and platelets are abundant but short-lived and
serve as a rich source of ROS, and therefore cause a signiﬁcant
risk of systemic oxidative stress. In addition to damaging cells,
tissues, and organs, ROS also affect the gas transport system
of red blood cells (RBCs). The ROS-mediated oxidation of Hb
(ferrous-Fe+2) to MetHb (ferric-Fe+3) results in severe methe-
moglobinemia, the lackof oxygen andH+bindingand transport
abilities. Snake envenoming is known to activate neutrophils,
andwe, therefore, investigatedwhether envenoming results in
systemic oxidative stress and perhaps hypoxia.42
Wedemonstrated that the venom from the Indian cobra (Naja
naja) induced a massive oxidative stress, an important, pre-
viously unrecognized toxic property of snake venom.Strikingly,
although antivenom neutralized much of the venom-induced
neurotoxicity, myotoxicity, and hemotoxicity, it did not neu-
tralize venom-induced oxidative stress. In fact, antivenom at
higher doses induced mild oxidative stress in mice.43–46
MetHb is itself a prooxidant molecule and, therefore, can
augment the magnitude of MetHb formation and hence hyp-
oxia. Furthermore, during methemoglobinemia, RBCs tend to
form aggregates and become vulnerable to lysis, which to the
causes additional physiological stress. Thus, during hypoxia,
there will be a gradual dip in the pH due to the accumulation of
H2CO3 (CO2 equivalent) and toxic metabolites in the systemic
compartment. Reactive oxygen species also inhibit energy
(adenosine triphosphate [ATP]) production by inhibiting electron
transport chain.47,48 Thus, venom-induced oxidative stress will
push the physiological system into a dangerous state of energy
depletion and fatal hypoxia. The brain is likely the organ at the
greatest risk because it is strictly aerobic and thought to use
about 10 times more energy per unit mass than other organs.49
Contractile organs such as lungs, heart, and diaphragm also
demandacontinuoussupplyofenergyandhence, theyalsoare
at particular risk of the effects of oxidative stress and hypoxia.
This led us to investigate modalities to prevent venom-
induced hypoxia, and we rationalized that protecting Hb in its
ferrous-Fe+2 form was the key objective. We preclinically
demonstrated, again for the ﬁrst time, that the antioxidant
melatonin not only reduced venom-induced oxidative stress
but also increased the survival rate of envenomed mice and
signiﬁcantly reduced the neutralizing dose of antivenom.42
Figure 3 demonstrates that none of themice survived after the
cobra venom injection, although three effective doses (EDs; it
is the amount of antivenom that neutralizes venom activity
in vitro) of antivenom were needed to neutralize the lethal ef-
fect of cobra venom. Interestingly, all mice injected with
venom survived after the administration of melatonin along
with one ED of antivenom (Figure 3).42 Our ﬁnding suggests
that the antioxidant administration could be used as a ﬁrst-aid
therapy to protect victims from developing a dangerous
hypoxic state.42 Melatonin is safe and penetrates into the
blood andcells quickly, and itsmetabolites (kynuramines) also
function as effective antioxidants. Moreover, all thesemolecules
aresafeand readilycleared fromthesystemiccirculation through
urine. Diffusion of venom toxins into the blood alters the hemo-
stasisbecauseof their procoagulant or anticoagulant properties.
Therefore, replacing the victim’s venom-contaminated blood
with normal blood might restore the altered hemostasis and
oxygen level, and reduce the systemic toxicities of snakebite
victims.50 Blood transfusion could be an effective treatment
where antivenom is inadequate. Fadare and Afolabi have
successfully shown that the whole blood transfusion could be
an alternative treatment for the management of snakebite in
resource-challenged areas.50 However, detailed investiga-
tions are needed to validate the outcome.
CONCLUSION
In conclusion, we have demonstrated that the fundamental
research into the pathogenesis of snake venom-induced
pathology can yield important newdata that have the potential
to lead to new treatment strategies—which need to be veriﬁed
FIGURE 3. Effect of melatonin and antivenom on Naja naja
venom–induced lethality in an in vivo challenge study. Melatonin and
antivenomwere administered (i.v.) independently, and in combination
at various time intervals after Nn venom injection (i.p.). Represent the
Kaplan–Meier survival analysis. P value was calculated using the log
rank (Mantel–Cox) test. *P<0.05, **P<0.01, and ***P<0.001. *Signiﬁcant
compared with Nn venom–injected group. Figure reprinted from Ref.
42 with permission. This ﬁgure appears in color at www.ajtmh.org.
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at the clinical level. Thus, injection of DNase 1 and application
of SVMP inhibitors at the bite site could prevent venom-
induced tissue necrosis. We also suggest that the administra-
tion of melatonin tablets at rural ﬁrst-aid centers may prevent
venom-induced hypoxic pathology while patients are trans-
ported to hospital for antivenom treatment.We hope that these
discoveries offer affordable, more culturally appropriate op-
tions to improve the management of snakebite mortality and
morbidity. We also illustrate the beneﬁt of basic research and
urge similar efforts by the scientiﬁc community, and investment
in this research by the governing bodies of the affected nations.
Received November 12, 2017. Accepted for publication November
30, 2018.
Published online January 21, 2019.
Acknowledgments: The author K. K. thanks the DST-SERB, EEQ/
2016/000193 for the ﬁnancial assistance.
Authors’ addresses: KesturuS.Girish, DOSR inBiochemistry, Tumkur
University, Tumakuru, India, E-mail: ksgbaboo@gmail.com. Gajanan
D. Katkar, Cardiovascular Research Lab, Institute of Biomedical Sci-
ences, Academia Sinica, Taipei, Taiwan, E-mail: gajanankatkar01@
gmail.com. Robert A. Harrison, Centre for Snakebite Research and
Interventions, Liverpool School of Tropical Medicine, Liverpool,
United Kingdom, E-mail: robert.harrison@lstmed.ac.uk. Kempaiah
Kemparaju, DOS in Biochemistry, University of Mysore, Mysuru,
India. E-mail: kemparajuom@gmail.com.
This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the
original author and source are credited.
REFERENCES
1. Mohapatra B, Warrell DA, Suraweera W, Bhatia P, Dhingra N,
Jotkar RM, Rodriguez PS, Mishra K, Whitaker R, Jha P, 2011.
Snakebite mortality in India: a nationally representative mor-
tality survey. PLoS Negl Trop Dis 5: e1018.
2. Habib AG, Kuznik A, Hamza M, Abdullahi MI, Chedi BA,
Chippaux JP, Warrell DA, 2015. Snakebite is under appreci-
ated: appraisal of burden from West Africa. PLoS Negl Trop
Dis 9: e0004088.
3. Harrison R, Hargreaves A, Wagstaff SC, Faragher B, Lalloo DG,
2009. Snake envenoming: a disease of poverty. PLoS Negl
Trop Dis 3: e569.
4. Girish KS, Kemparaju K, 2011. Overlooked issues of snakebite
management: time for strategic approach.Curr TopMedChem
11: 2494–2508.
5. WHO, 2009.NeglectedTropical Diseases: Snakebite. Available at:
http://www.who.int/neglected_diseases/diseases/snakebites/
en/index.html. Accessed August 12, 2009.
6. Editorial, 2015. Snake bite-the neglected tropical disease. Lancet
386: 1110.
7. Calmette A, 1896. The treatment of animals poisoned with snake
venom by the injection of antivenomous serum. Br Med J 2:
399–400.
8. Chung KT, Biggers CJ, 2001. Albert Le´on Charles Calmette
(1863-1933) and the antituberculous BCG vaccination. Perspect
Biol Med 44: 379–389.
9. Laustsen AH et al., 2018. Pros and cons of different therapeutic
antibody formats for recombinant antivenom development.
Toxicon 146: 151–175.
10. Gutie´rrez JM, Leo´n G, Burnouf T, 2011. Antivenoms for the
treatment of snakebite envenomings: the road ahead. Biologi-
cals 39: 129–142.
11. Morais JF, deFreitasMCW,Yamaguchi IK, dosSantosMC,Diasda
Silva W, 1994. Snake antivenoms from hyperimmunized horses:
comparisonof the antivenomactivity and biological properties of
their whole IgG and F (ab9)2 fragments. Toxicon 32: 725–734.
12. Ismail M, Abd-Elsalam MA, Al-Ahaidib MS, 1998. Pharmacoki-
netics of 125I-labelled Walterinnesiaaegyptia venom and its
speciﬁc antivenins: ﬂash absorption and distribution of the
venom and its toxin versus slow absorption and distribution of
IgG, F(ab9)2 and Fab of the antivenin. Toxicon 36: 93–114.
13. Ismail M, Abd-Elsalam MA, 1998. Pharmacokinetics of 125I-
labelled IgG, F(ab9)2 and Fab fractions of scorpion and snake
antivenins: merits and potential for therapeutic use. Toxicon
36: 1523–1528.
14. Rojas G, Jime´nez JM, Gutie´rrez JM, 1994. Caprylic acid fraction-
ation of hyperimmune horse plasma: description of a simple
procedure for antivenom production. Toxicon 32: 351–363.
15. Leo´n G, Monge M, Rojas E, Lomonte B, Gutie´rrez JM, 2001.
Comparison between IgG and F(ab’)(2) polyvalent antivenoms:
neutralization of systemic effects induced by Bothropsasper
venom inmice, extravasation tomuscle tissue, andpotential for
induction of adverse reactions. Toxicon 39: 793–801.
16. Eursakun S, Simsiriwong P, Ratanabanangkoon K, 2012. Studies
on the fractionation of equine antivenom IgG by combina-
tions of ammonium sulfate and caprylic acid. Toxicon 60:
1022–1029.
17. Al-Abdulla I, Casewell NR, Landon J, 2014. Single-reagent one-
step procedures for the puriﬁcation of ovine IgG, F(ab’)2 and
Fab antivenoms by caprylic acid. J Immunol Methods 402:
15–22.
18. Be´nard-Valle M, Neri-Castro EE, Fry BG, 2005. Antivenom re-
search and development. Fry BG, ed. Venomous Reptiles and
Their Toxins: Evolution, Pathophysiology and Biodiscovery.
Oxford, United Kingdom: Oxford University Press, 61–72.
19. WHO, 2017. Snake Antivenom Immunoglobulins. Available at:
http://www.who.int/bloodproducts/snake_antivenoms/en/.
Accessed September 21, 2018.
20. Harrison RA et al., 2017. Preclinical antivenom-efﬁcacy testing
reveals potentially disturbing deﬁciencies of snakebite treat-
ment capability in East Africa. PLoS Negl Trop Dis 11:
e0005969.
21. Gras S, Plantefe`ve G, Baud F, Chippaux JP, 2012. Snakebite on
the hand: lessons from two clinical cases illustrating difﬁculties
of surgical indication. J Venom Anim Toxins Incl Trop Dis 18:
467–477.
22. De Silva HA, Ryan NM, de Silva HJ, 2016. Adverse reactions to
snake antivenom, and their prevention and treatment. Br J Clin
Pharmacol 81: 446–452.
23. Daltry JC, Wu¨ster W, Thorpe RS, 1996. Diet and snake venom
evolution. Nature 379: 537–540.
24. Daltry JC, Ponnudurai G, ShinCK, TanNH, ThorpeRS,Wu¨sterW,
1996. Electrophoretic proﬁles and biological activities: In-
traspeciﬁc variation in the venom of the Malayan pit viper
(Calloselasma rhodostoma). Toxicon 34: 67–79.
25. Shashidharamurthy R, Jagadeesha DK, Girish KS, Kemparaju K,
2002. Variations in biochemical and pharmacological proper-
ties of Indian cobra (Naja naja naja) venom due to geographical
distribution.Mol Cell Biochem 229: 93–101.
26. Casewell NR,Wagstaff SC,Wu¨sterW, Cook DA, Bolton FM, King
SI, Pla D, Sanz L, Calvete JJ, Harrison RA, 2014. Medically
important differences in snake venomcomposition are dictated
bydistinct postgenomicmechanisms.ProcNatl AcadSciUSA
111: 9205–9210.
27. Amazonas DR et al., 2018. Molecular mechanisms underlying
intraspeciﬁc variation in snake venom. J Proteomics 181:
60–72.
28. Shashidharamurthy R, Kemparaju K, 2007. Region-speciﬁc neu-
tralization of Indian cobra (Naja naja) venom by polyclonal an-
tibody raised against the eastern regional venom: a comparative
study of the venoms from three different geographical distribu-
tions. Int Immunopharmacol 7: 61–69.
29. Katkar GD, Sundaram MS, NaveenKumar SK, Swethakumar B,
Sharma RD, Paul M, Vishalakshi GJ, Devaraja S, Girish KS,
Kemparaju K, 2016. NETosis and lack of DNase activity are key
factors in Echis carinatus venom-induced tissue destruction.
Nat Commun 7: 11361.
30. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y,
Weiss DS, Weinrauch Y, Zychlinsky A, 2004. Neutrophil extra-
cellular traps kill bacteria. Science 303: 1532–1535.
31. Fuchs TA, Brill A, Wagner DD, 2012. Neutrophil extracellular trap
(NET) impact on deep vein thrombosis. Arterioscler Thromb
Vasc Biol 32: 1777–1783.
THERAPEUTIC STRATEGIES FOR SNAKEBITE TREATMENT 1047
32. Robb CT, Dyrynda EA, Gray RD, Rossi AG, Smith VJ, 2014. In-
vertebrate extracellular phagocyte traps show that chromatin is
an ancient defence weapon. Nat Commun 5: 1–11.
33. Xu J, Zhang X, Pelayo R, Monestier M, Ammollo CT, Semeraro F,
Taylor FB, Esmon NL, Lupu F, Esmon CT, 2009. Extracellular
histones are major mediators of death in sepsis. Nat Med 15:
1318–1321.
34. KaplanMJ, RadicM, 2012. Neutrophil extracellular traps: double-
edged swords of innate immunity. J Immunol 189: 2689–2695.
35. Sarratt KL, Chen H, Zutter MM, Santoro SA, Hammer DA, Kahn
ML, 2005. GPVI and α2β1 play independent critical roles during
platelet adhesion and aggregate formation to collagen under
ﬂow. Blood 106: 1268–1277.
36. Ishida Y, Gao JL, Murphy PM, 2008. Chemokine receptor
CX3CR1 mediates skin wound healing by promoting macro-
phage and ﬁbroblast accumulation and function. J Immunol
180: 569–579.
37. Leitinger B, 2011. Transmembrane collagen receptors. Annu Rev
Cell Dev Biol 27: 265–290.
38. Barun P, Yoon DS, Lee JH, Lee YM, Kim DK, 2012. Collagen I
enhances functional activities of human monocyte-derived
dendritic cells via discoidin domain receptor 2. Cell Immunol
278: 95–102.
39. Leitinger B, 2014. Discoidin domain receptor functions in physi-
ological and pathological conditions. Int Rev Cell Mol Biol
310: 39–87.
40. Kumar AH,Martin K, Turner EC, Buneker CK, DorghamK, Deterre
P, Caplice NM, 2013. Role of CX3CR1 receptor in monocyte/
macrophage driven neovascularization. PLoS One 8: e57230.
41. Katkar GD, Sharma RD, Vishalakshi GJ, Naveenkumar SK,
Madhur G, Thushara RM, Narender T, Girish KS, Kemparaju K,
2015. Lupeol derivative mitigates Echis carinatus venom-
induced tissue destruction by neutralizing venom toxins and
protecting collagen and angiogenic receptors on inﬂammatory
cells. Biochim Biophys Acta 1850: 2393–2409.
42. Sharma RD, Katkar GD, Sundaram MS, Paul M, NaveenKumar
SK, Swethakumar B, Hemshekhar M, Girish KS, Kemparaju K,
2015. Oxidative stress-induced methemoglobinemia is the si-
lent killer during snakebite: a novel and strategic neutralization
by melatonin. J Pineal Res 59: 240–254.
43. SebastinSanthosh M, Hemshekhar M, Thushara RM, Devaraja S,
Kemparaju K, Girish KS, 2013. Viperarusselli venom-induced
oxidative stress and hematological alterations: amelioration by
crocin a dietary colorant. Cell Biochem Funct 31: 41–50.
44. KatkarGD,SundaramMS,HemshekharM,SharmaDR,Santhosh
MS, Sunitha K, Rangappa KS, Girish KS, Kemparaju K, 2014.
Melatonin alleviates Echis carinatus venom-induced toxicities
by modulating inﬂammatory mediators and oxidative stress.
J Pineal Res 56: 295–312.
45. Sunitha K, Hemshekhar M, Thushara RM, Santhosh MS,
Sundaram MS, Kemparaju K, Girish KS, 2015. Inﬂammation
and oxidative stress in viper bite: an insight within and beyond.
Toxicon 98: 89–97.
46. Sharma RD, Katkar GD, Sundaram MS, Swethakumar B, Girish
KS, Kemparaju K, 2017. Melatonin inhibits snake venom and
antivenom induced oxidative stress and augments treatment
efﬁcacy. Acta Trop 169: 14–25.
47. Zhang Y, Marcillat O, Giulivi C, Ernster L, Davies KJ, 1990. The
oxidative inactivation of mitochondrial electron transport
chain components and ATPase. J Biol Chem 265: 16330–
16336.
48. Buttke TM, Sandstrom PA, 1995. Redox regulation of pro-
grammed cell death in lymphocytes. Free Radic Res 22:
389–397.
49. Pellerin L, Magistretti PJ, 2003. Food for thought: challenging the
dogmas. J Cereb Blood Flow Metab 23: 1282–1286.
50. Fadare JO, Afolabi OA, 2012. Management of snake bite in
resource-challenged setting: a review of 18months experience
in a Nigerian hospital. J Clin Med Res 4: 39–43.
1048 GIRISH AND OTHERS
